Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 6/20 | 0.50 |
| ▸ | CDK8 | P49336 | 6/20 | 0.50 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 4/20 | 0.42 |
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539335 | 0.78 | CAMKK2 (0.48) | CAMKK2PIM1CDC7ROCK1MAP2K4 | |
| SCHEMBL3189066 | 0.76 | AURKA (0.59) | — | |
| SCHEMBL4115515 | 0.73 | JAK2 (0.54) | CCNCCDK8PIM1ROCK1MAP2K4 | |
| SCHEMBL1384475 | 0.72 | CAMKK2 (0.46) | CAMKK2MAP2K1RIPK1 | |
| SCHEMBL29732854 | 0.72 | CAMKK2 (0.46) | CAMKK2MAP2K1RIPK1 | |
| SCHEMBL3351246 | 0.71 | HDAC1 (0.40) | CAMKK2PIM1 | |
| SCHEMBL5536781 | 0.71 | CAMKK2 (0.47) | CAMKK2ROCK1MAP2K4MAP2K1 | |
| SCHEMBL5541202 | 0.71 | CAMKK2 (0.39) | CAMKK2PIM1CDC7ROCK1RIPK1 | |
| SCHEMBL5536725 | 0.70 | CAMKK2 (0.41) | CAMKK2PIM1CDC7ROCK1MAP2K4 | |
| SCHEMBL1513056 | 0.70 | ALDH1A1 (0.55) | PIM1PIM2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122185-A1 | Bicyclic inhibitors of Rho kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122185-A1 | Bicyclic inhibitors of Rho kinase | ROCK1, ROCK2, RHOA | CCNC 540/4885CDK8 412/4885CAMKK2 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.